EAGLE, Idaho, July 20, 2017 -- PetIQ, Inc. (“PetIQ” or the “Company”) announced today the pricing of its initial public offering of 6,250,000 shares of the Company’s Class A common stock at a public offering price of $16.00 per share. All of the shares of Class A common stock are being offered by the Company. The shares are expected to begin trading on the Nasdaq Stock Market on July 21, 2017 under the ticker symbol “PETQ.” In addition, PetIQ has granted the underwriters a 30-day option to purchase from PetIQ up to an additional 937,500 shares of its Class A common stock at the initial public offering price, less the underwriting discount and commissions.
The closing of the offering is expected to occur on July 26, 2017, subject to the satisfaction of customary closing conditions.
Jefferies and William Blair are acting as book-running managers for the proposed offering. Oppenheimer & Co, Raymond James, and SunTrust Robinson Humphrey are acting as co-managers.
A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering will be made only by means of a prospectus. A copy of the final prospectus relating to this offering, when available, may be obtained from any of the following sources: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 547-6340 or email: [email protected]; William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, telephone: (800) 621-0687 or email: [email protected]; Oppenheimer & Co. Inc. Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, telephone: (212) 667-8563, or email: [email protected]; Raymond James & Associates, Inc., 880 Carillon Parkway, St. Petersburg, FL 33716, telephone: (800) 248-8863, or email: [email protected]; SunTrust Robinson Humphrey, Inc., 303 Peachtree Street, Atlanta, GA 30308, telephone: (800) 685-4786 or email: [email protected].
About PetIQ, Inc.
PetIQ is a pet medication and wellness company bringing a broad portfolio of veterinarian-recommended over-the-counter pet medications to a network of leading national retail stores across the mass, club, grocery, pharmacy, and e-commerce channels. PetIQ’s mission is to deliver pet owners a pipeline of innovative products that combine leading technology with affordability, choice and convenience.
Contacts Media Cory Ziskind ICR 646-277-1232 [email protected] Investors Katie Turner ICR 646-277-1228 [email protected]


First Western Ship Transits Strait of Hormuz Since Iran War Began
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Britain Courts Anthropic Amid US Defense Department Dispute
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 



